Maria Beatrice Saccardo

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Elena Ardini, Maria Menichincheri, Patrizia Banfi et al. · Molecular Cancer Therapeutics · 2016 · 308 citations · Full text

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

Maria Menichincheri, Elena Ardini, Paola Magnaghi et al. · Journal of Medicinal Chemistry · 2016 · 294 citations · Full text

Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors

R Bossi, Maria Beatrice Saccardo, Elena Ardini et al. · Biochemistry · 2010 · 165 citations

Engineering, Molecular Biology, Anaplastic Lymphoma Kinase +18

The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

Elena Ardini, Roberta Bosotti, Andrea Borgia et al. · Molecular Oncology · 2014 · 151 citations · Full text

Trka Kinase Inhibition, Pathology, Cancer Biology +21

Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease

Luisa Bartorelli, C Giraldi, Maria Beatrice Saccardo et al. · Current Medical Research and Opinion · 2005 · 77 citations